Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

557 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
Kalra S, Atkin S, Cervera A, Das AK, Demir O, Demir T, Fariduddin M, Vo KT, Ku BJ, Kumar A, Latif ZA, Malek R, Matawaran BJ, Mehta R, Tran NQ, Panelo A, Ruder S, Saldana JR, Shaikh KA, Shakya A, Shrestha D, Unnikrishnan AG. Kalra S, et al. Among authors: atkin s. Adv Ther. 2018 Jul;35(7):928-936. doi: 10.1007/s12325-018-0712-2. Epub 2018 May 23. Adv Ther. 2018. PMID: 29796928 Review.
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK; DURATION-4 Study Group. Russell-Jones D, et al. Diabetes Care. 2012 Feb;35(2):252-8. doi: 10.2337/dc11-1107. Epub 2011 Dec 30. Diabetes Care. 2012. PMID: 22210563 Free PMC article. Clinical Trial.
Insulin degludec--a new-generation basal insulin.
Wakil A, Atkin SL. Wakil A, et al. Expert Opin Biol Ther. 2012 May;12(5):539-42. doi: 10.1517/14712598.2012.668880. Epub 2012 Mar 24. Expert Opin Biol Ther. 2012. PMID: 22444163
Correction to: Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
Kalra S, Atkin S, Cervera A, Das AK, Demir O, Demir T, Fariduddin M, Vo KT, Ku BJ, Kumar A, Latif ZA, Malek R, Matawaran BJ, Mehta R, Tran NQ, Panelo A, Ruder S, Saldana JR, Shaikh KA, Shakya A, Shrestha D, Unnikrishnan AG. Kalra S, et al. Among authors: atkin s. Adv Ther. 2018 Jul;35(7):937-938. doi: 10.1007/s12325-018-0728-7. Adv Ther. 2018. PMID: 29882121
Three-year efficacy of complex insulin regimens in type 2 diabetes.
Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK; 4-T Study Group. Holman RR, et al. N Engl J Med. 2009 Oct 29;361(18):1736-47. doi: 10.1056/NEJMoa0905479. Epub 2009 Oct 22. N Engl J Med. 2009. PMID: 19850703 Free article. Clinical Trial.
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, Bain S, Johansen T, Begtrup K, Birkeland KI; NN1250-3668 (BEGIN FLEX) Trial Investigators. Meneghini L, et al. Among authors: atkin sl. Diabetes Care. 2013 Apr;36(4):858-64. doi: 10.2337/dc12-1668. Epub 2013 Jan 22. Diabetes Care. 2013. PMID: 23340894 Free PMC article. Clinical Trial.
Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, Larsen J, Tamer SC, Bain SC; NN1250-3770 (BEGIN: Flex T1) Trial Investigators. Mathieu C, et al. J Clin Endocrinol Metab. 2013 Mar;98(3):1154-62. doi: 10.1210/jc.2012-3249. Epub 2013 Feb 7. J Clin Endocrinol Metab. 2013. PMID: 23393185 Free PMC article. Clinical Trial.
557 results